Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer

References

• ParkinDMBrayFFerlayJPisaniPEstimating the world cancer burden: Globocan 2000Int J Cancer20019415315611668491
   PubMed Web of Science ®Google Scholar
• SchrumpDSAltorkiNKHenschkeCLCarterDTurrisiATGutierrezMENSCLCCancer: Principles and Practice of Oncology7th edPhiladelphia (PA)Lippincott Williams & Wilkins2005753809
   Google Scholar
• BastinKTCurleyRNSCLC: Current & future therapeutic managementDrugs199549362375
   PubMed Web of Science ®Google Scholar
• D’AddarioGFelipENon-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-upAnn Oncol200920Suppl 46670
   Google Scholar
• FelipERosellRClinical experience with erlotinib in non-small-cell lung cancerDrugs Today200642314715616628257
   PubMed Web of Science ®Google Scholar
• MoyerJDBarbacciEGIwataKKInduction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res199757483848489354447
   PubMed Web of Science ®Google Scholar
• PollackVASavageDMBakerDAInhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther199929173974810525095
   PubMed Web of Science ®Google Scholar
• SalomonDSBrantRCiardielloFEpidermal growth factor-related peptides and their receptors in human malignancesCrit Rev Oncol Haematol199519183232
   PubMed Web of Science ®Google Scholar
• Pfizer IncCP-358,774 Investigator Brochure 1999Groton, CT, USA19993
   Google Scholar
• MartinPKellyCCarneyDEpidermal growth factor receptor-targeted agents for lung cancerCancer Control200613212914016735987
   PubMedGoogle Scholar
• HidalgoMSiuLLNemunaitisJPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol2001193267327911432895
   PubMed Web of Science ®Google Scholar
• MiltonDTAzzoliCGHeelanRTA phase I/II study of weekly high dose erlotinib in previously treated patients with non-small cell cancerCancer20061071034104116878326
   PubMed Web of Science ®Google Scholar
• Perez-SolerRChachouaAHammondLADeterminants of tumor response and survival with erlotinib in patients with non-small-cell lung cancerJ Clin Oncol2004223238324715310767
   PubMed Web of Science ®Google Scholar
• GiacconeGGallegos RuizMLe ChevalierTErlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II studyClin Cancer Res2006126049605517062680
   PubMed Web of Science ®Google Scholar
• JackmanDMYeapBYLindemanNIPhase II clinical trial of chemotherapy-naıve patients over 70 years of age treated with erlotinib for advanced non-small-cell lung cancerJ Clin Oncol20072576076617228019
   PubMed Web of Science ®Google Scholar
• HeskethPJChanskyKWozniakAJErlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a PS of 2: a SWOG Phase II trial (S0341)Proceedings of the American Society Clinical Oncology [Abstract 7536]2007Chicago
   Google Scholar
• JackmanDLindemanNILuccaJPhase II study of erlotinib in chemo-nave women with advanced pulmonary adenocarcinomaProceedings of the American Society Clinical Oncology [Abstract 7591]2007Chicago
   Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• BezjakATuDSeymourLSymptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol2006243831383716921034
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2005235892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAResults of a phase III trial of erlotinib (OSI-774) combined with cisplatin and GC chemotherapy in advanced non-small cell lung cancer (NSCLC)J Clin Oncol200422Suppl 14619s
   Web of Science ®Google Scholar
• GatzemeierUArdizzoniAHorwoodKErlotinib in non-small cell lung cancer (NSCLC): interim safety analysis of the TRUST studyJ Clin Oncol200725 Abstract 764517146105
   PubMed Web of Science ®Google Scholar
• GroenHJMBarataFMcDermottREfficacy of erlotinib in >4000 patients with advanced non-small-cell lung cancer (NSCLC): analysis of the European subpopulation of the trust studyESMO Abstract 266PSweden20089
   Google Scholar
• TiseoMGridelliCCascinuSAn expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from ItalyLung Cancer20096419920618951651
   PubMed Web of Science ®Google Scholar
• HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER 1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancerJ Clin Oncol2005232544255515753462
   PubMed Web of Science ®Google Scholar
• FehrenbacherLO’ NeillVBelaniCPA phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non small cell lung cancerJ Clin Oncol200624Suppl 18379s
   Web of Science ®Google Scholar
• MillerVAO’ConnorPSohCA randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)ASCO Abstract LBA80022009
   Google Scholar
• HainsworthJHerbstRA Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA)Paper presented at: 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology2008 Nov 13–15Chicago
   Google Scholar
• ThatcherNFirst- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global viewBMC Proc20082Suppl 2S3
   Google Scholar
• ClarkGMZborowskiDMSantabarbaraPSmoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21Clin Lung Cancer2006738939416800964
   PubMed Web of Science ®Google Scholar
• Perez-SolerRChachowaAHammondLADeterminants of tumor response and survival with erlotinib in patients with non small cell lung cancerJ Clin Oncol2004223238324715310767
   PubMed Web of Science ®Google Scholar
• GridelliCBareschinoMASchiettinoCErlotinib in non small cell lung cancer treatment: current status and future developmentOncologist20071284084917673615
   PubMed Web of Science ®Google Scholar
• AmadorMLOppenheimerDPereaSAn epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitorsCancer Res2004649139914315604284
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMBunnPAEpidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol2003213798380712953099
   PubMed Web of Science ®Google Scholar
• MillerVAZakowskiMRielyGJEGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): results of a prospective phase II trialJ Clin Oncol. Proc ASCO Abstract 700320062418S
   Web of Science ®Google Scholar
• TsaoMSSakuradaACutzJCErlotinib in lung cancer-molecular and clinical predictors of outcomeN Engl J Med200535313314416014883
   PubMed Web of Science ®Google Scholar
• HirschFRVarrella-GarciaMBunnPAFluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a Phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLCProceedings of the American Society Clinical Oncology Abstract 7570
   Google Scholar
• ShigematsuHLinLTakahashiTClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst20059733934615741570
   PubMed Web of Science ®Google Scholar
• JohnsonBEJannePAEpidermal growth factor receptor mutations in patients with non-small-cell lung cancerCancer Res2005657525752916140912
   PubMed Web of Science ®Google Scholar
• GiacconeGEpidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancerJ Clin Oncol2005233235324215886311
   PubMed Web of Science ®Google Scholar
• EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol2005235900590916043828
   PubMed Web of Science ®Google Scholar
• GatzemeierUHellerAFoernzlerDExploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy ± erlotinib (TALENT)Proceedings of the American Society Clinical Oncology Abstract 70282005
   Google Scholar
• AgeroALDuszaSWBenvenuto-AndradeCDermatologic side effects associated with the epidermal growth factor receptor inhibitorsJ Am Acad Dermatol20065565767017010747
   PubMed Web of Science ®Google Scholar
• BusamKJCapodieciPMotzerRCutaneous side-effects in cancer patients treated with the epidermal growth factorBr J Dermatol20011441169117611422037
   PubMed Web of Science ®Google Scholar
• ClarkGPerez-SolerRSiuLRash severity is predictive of increased survival with erlotinib HCIProc Am Soc Clin Oncol200322196
   Web of Science ®Google Scholar
• Perez-SolerRCan rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?Oncology2003172328
   PubMedGoogle Scholar
• GanjooKNWakeleeHReview of erlotinib in the treatment of advanced non-small-cell lung cancerBiologics20071433534619707304
   PubMedGoogle Scholar
• RosellRMoranTQueraltTScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• GridelliCButtsCCiardielloFAn international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trialClin Lung Cancer720089423523818650174
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLSaturn: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLCJ Clin Oncol200927Suppl Abstract 800115s
   Google Scholar